Verve Therapeutics price target raised to $15 from $14 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Verve Therapeutics (VERV) to $15 from $14 and keeps a Buy rating on the shares. The firm says the Q2 VERVE-101 data readout “should constitute a major inflection point” for the shares. It expects the data to be positive.